Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rina-S Plus Standard of Care in Recurrent Platinum-Sensitive Ovarian Cancer
NCT07225270Phase 3Recruiting
- Sponsor
- Genmab
- Start
- Apr 2026
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of rinatabart sesutecan in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Genmab. Started Apr 2026; status: recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT07225270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225270.